|Podcasts|January 19, 2023

Let’s Get Social: The Ascendancy of Social Media to the Top of the Media Mix

Amanda Powers-Han, chief marketing officer at Greater Than One, talks with senior editor Fran Pollaro about the ascension of social media as an incremental investment to one that is foundational. The pair delve into the focus on HCPs, especially in the rare disease space, building out sophisticated targeting strategies via multiple data partners, and the different uses across the social landscape, especially with video—from HCP social sites like Dermo and Medscape to the topical Twitter and its recognized peers like TikTok, Facebook, LinkedIn, and YouTube.

About the speaker

Amanda Powers-Han is an established healthcare marketing and communications leader with over 20 years of experience and a proven track record of building brands, leading clients, and helping
propel Greater Than One into its position today. As CMO, Amanda is responsible for building strategic alliances, identifying new client opportunities, and leading marketing and media efforts.

About the PharmExec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the scienceof success. Podcast episodes examine current trends, key conferences, and critical topics in the
bio/pharmaceutical industry.

Listen to this podcast on SoundCloudSpotifyGoogle Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.